https://www.thebodypro.com/tag/id-week

IDWeek

The Latest

HIV Research Preview for IDWeek 2016 Img

HIV Research Preview for IDWeek 2016

Here's a look at some of the noteworthy HIV research being presented at IDWeek 2016 in New Orleans from Oct. 25 to 30.

Do HIV-Positive People Have Worse Flu Symptoms, or Do Physicians Just Think They Do? Img

Do HIV-Positive People Have Worse Flu Symptoms, or Do Physicians Just Think They Do?

Flu season can bring anxiety for people living with HIV and their health care providers. But do HIV-positive people have more severe symptoms of flu than people who are not living with HIV? In this interview, Christina Schofield, M.D., shares her stu...

Could the HIV Treatment-as-Prevention Model Work for Hepatitis C? Img

Could the HIV Treatment-as-Prevention Model Work for Hepatitis C?

HIV treatment as prevention has become a well-known and powerful tool in the global HIV response. In this interview, Mark Sulkowski, M.D., discusses whether a similar approach could be used in the prevention of hepatitis C.

What Can We Learn From HIV-Positive Patients Who Control the Virus After Stopping Treatment? Img

What Can We Learn From HIV-Positive Patients Who Control the Virus After Stopping Treatment?

In this interview, Matthew Perkins, M.D., discusses the interest in post-treatment controllers -- people living with HIV who are able to control the virus for a period of time after stopping therapy -- and the first study such individuals.

What's the Effect of Genvoya, the Newest Single-Tablet Regimen, on Older Adults Living With HIV? Img

What's the Effect of Genvoya, the Newest Single-Tablet Regimen, on Older Adults Living With HIV?

In this interview, Eric Daar, M.D. discusses how the new coformulation elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (Genvoya) measures up to its predecessor, specifically among older adults.

What Helps and What Hinders Participation in HIV Clinical Trials? Img

What Helps and What Hinders Participation in HIV Clinical Trials?

In this interview, Prema Menezes, Ph.D., discusses what motivates people living with HIV to enter into clinical trials and what stops those who have never participated from volunteering.

The Challenges of Assessing Guideline Adherence in a Rapidly Changing Treatment Landscape Img

The Challenges of Assessing Guideline Adherence in a Rapidly Changing Treatment Landscape

With more than 20 approved HIV antiretrovirals in the United States, physicians have many options for their patients -- they can choose one of the "preferred" drug regimens or deviate from treatment guidelines entirely.

Health Outcomes Worse for HIV-Positive Black Men Even Despite Equal Access Img

Health Outcomes Worse for HIV-Positive Black Men Even Despite Equal Access

A new study finds significant health disparities between black and white men with HIV, even though these men had equal access to health care through the Veterans Administration (VA).

The Most Important HIV Study at IDWeek 2015 Img

The Most Important HIV Study at IDWeek 2015

Paul Sax, M.D., breaks down another HIV treatment switching study -- this one from IDWeek 2015 -- the results of which supported switching to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide plus darunavir (Prezista) for treatment-experien...

Why Microbicides for HIV Prevention Are Still Necessary in the Treatment-as-Prevention Era Img

Why Microbicides for HIV Prevention Are Still Necessary in the Treatment-as-Prevention Era

How do things stand with the development of topical agents for HIV prevention? In the age of oral pre-exposure prophylaxis (PrEP) and treatment as prevention, do microbicides matter anymore?